Overexpression of the TGF-β antagonist Smad7 in endometrial cancer

Smad7 appears to be upregulated in endometrial cancers compared to normal endometrium. Furthermore, high Smad7 gene expression was associated with a shorter time to recurrence. Given that many endometrial cancers have been shown to be TGF-β-unresponsive, Smad7 should be investigated as a potential target to restore TGF-β responsiveness and limit tumor growth.